P/E Ratio

The P/E ratio compares a stock's price to its earnings per share, and a reading of 78.2x means investors are paying $78.20 for every $1 of Bio-Techne's annual earnings.

This is far above the healthcare sector median of 27.6x, placing the stock in the 95th percentile among its peers, indicating it is one of the most expensive stocks in the sector by this measure. No trend data is available because the year-over-year and quarter-over-quarter changes are both listed as N/A, so there is no basis to assess whether the multiple is expanding or contracting. The combination of a very high P/E and no observable trend suggests elevated valuation risk if earnings fail to meet expectations, but it also reflects market pricing for future growth that has not yet materialized—creating both opportunity and hazard. This metric does not support a NEUTRAL verdict; the extreme premium relative to peers typically signals bullish sentiment, but without trend confirmation, it introduces enough uncertainty to keep the overall rating neutral.

Frequently Asked Questions

Closest Sector Peers